

Special Issue

Retinoblastoma—Current Therapeutic Challenges and Promising New Approaches

Message from the Guest Editors

Retinoblastoma (RB) is the most common primary intraocular tumor with an incidence of 1 in 14000 to 1 in 20000 per childbirths. Untreated, the tumor expands, may extend beyond the eye and develop metastatic spread. The advent of novel routes of chemotherapy administration, including intra-arterial, intravitreal and intracameral injections, has considerably improved the overall eye survival rate, eradicating the need for external beam radiotherapy, eliminating the risk of radio-induced malignancies, and reducing the indications for systemic chemotherapy. In this context, we welcome reviews and research articles summarizing the current state of the art in RB screening and treatment and future challenges as well as basic, preclinical and clinical studies. We are looking for studies on genes and miRNAs involved in the etiology and progression of RB, the potential impact of liquid biopsy and the development of chemoresistances. Other possible topics are promising new approaches including charged particle treatment, toxic chorioretinopathies, tumor invasion, metastasis and recurrence.

Guest Editors

Prof. Dr. Nicole Dünker
Prof. Dr. Norbert Bornfeld
Prof. Dr. Francis L. Munier

Deadline for manuscript submissions

closed (28 February 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/39986

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)